Products & Innovation / Clinical Trials

The ReSPECT™ clinical trials.

The ReSPECT™ program is evaluating REYOBIQ™ (rhenium Re 186 obisbemeda), an investigational targeted radiotherapy, in three clinical trials across recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancer.

Clinical Trials

One therapy across three cancers.

ReSPECT™ evaluates REYOBIQ™ using the same formulation in each trial, delivered by the route that fits the disease: into the tumor for glioblastoma and pediatric brain cancer, into the cerebrospinal fluid for leptomeningeal metastases.

ReSPECT-GBM: recurrent glioblastoma

Phase 2 enrollment completed. Administered directly into the tumor by convection-enhanced delivery. Supported by the National Cancer Institute (NCI), as well as Orphan Drug and Fast Track designations.

ReSPECT-LM: leptomeningeal metastases

Phase 1 dose optimization, enrolling. Delivered into the cerebrospinal fluid. Funded in part by a $17.6M grant from CPRIT. Orphan Drug Designation in breast cancer and lung cancer patients and Fast Track Designation.

ReSPECT-PBC: pediatric brain cancer

Phase 1, open for enrollment. For ependymoma and high-grade glioma. Supported by a $3M U.S. Department of Defense grant; FDA Orphan Drug Designation in pediatric malignant gliomas.

Smiling woman seated for an interview in a softly lit room.

Considering a trial? Start here.

Clinical trials can be one path worth understanding, and whether one is right for you is a decision for you and your care team. To see which ReSPECT™ trials are enrolling, check eligibility, and find a participating site, visit the ReSPECT™ trials site.

Is your patient a candidate?

REYOBIQ™ is investigational and administered directly to the disease site, by convection-enhanced delivery into the tumor or into the cerebrospinal fluid through an Ommaya reservoir, depending on the indication.

Clinical rationale by indication.

Why locoregional delivery is being studied where systemic therapy is limited by the blood-brain barrier.

Eligibility at a glance.

Phase, enrollment status, and key inclusion and exclusion criteria for ReSPECT-GBM, ReSPECT-LM, and ReSPECT-PBC.

Participating sites.

Enrolling centers by trial, with current status.

How referral works.

What to send, who receives it, and what happens after a patient is referred.

Protocols and published data.

Protocol summaries, plus Phase 1 results and congress presentations to date.

Following the science.

The ReSPECT™ Programs’ findings are shared as they’re published and presented. Phase 1 REYOBIQ™ results in recurrent glioblastoma were published in Nature Communications, and ReSPECT-LM data have been presented at the SNO Annual Conference.